Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases
BARNETCHE, Thomas
Hôpital Pellegrin
Service de rhumatologie
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Haut-Lévêque [CHU Bordeaux]
Service de Rhumatologie [CHU Pellegrin]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] [FHU ACRONIM]
Hôpital Pellegrin
Service de rhumatologie
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Haut-Lévêque [CHU Bordeaux]
Service de Rhumatologie [CHU Pellegrin]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] [FHU ACRONIM]
RICHEZ, Christophe
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
< Reduce
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Language
EN
Article de revue
This item was published in
Joint Bone Spine. 2021-05-26, vol. 88, n° 6
English Keywords
COVID-19
DMARD
Hydroxychloroquine
Inflammatory rheumatic and musculoskeletal diseases
SARS COV-2 evolution
SARS CoV-2 tests
Collections